Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

SARS-CoV2 Infection Clinical Trial

— GETCOV-2  

Official title:

Epidemiologic, Clinical Characteristics and Risk Factors of Critical Ill Patients Admitted to the ICU for Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04948242
• Other study ID #: COVID-19/SEMICYUC
• Status: Recruiting
• Start date: December 12, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: April 2023
• Source: Hospital Universitari Joan XXIII de Tarragona.
• Contact: Alejandro Rodríguez Oviedo, MD,PhD,MsC
• Phone: +34977295818
• Email: ahr1161[@]yahoo.es
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A multicenter observational, prospective cohort study that consisted of a large-scale data source of hospital ICU admissions and patient-level clinical data in Spain.

The main objective is to develop a national database belonging to SEMICYUC (Spanish Society of Critical Care) to describe epidemiological and clinical characteristics and risk factors related to ICU mortality in critically ill patients admitted to ICU due to severe COVID-19 in Spain.

Description:

Design: A multicenter observational, prospective cohort study

Setting: Intensive Care Units

Subjects: Adult Critical patients admitted to ICU with severe community-acquired pneumonia due to confirmed SARS CoV-2 infection (COVID-19).

Data Collection and Validation Data was obtained from a voluntary registry created by Spanish Society of Intensive Care Medicine-SEMICYUC. All consecutive cases admitted to the ICU were collected.

There were no patients excluded from the analysis that was enrolled to participating ICU and met criteria.

Data were collected using a paper CRF (case Report Form). CRF collect and record all protocol-required information, which is transcribed from patient source documents, such as hospital records and laboratory reports during the patient's participation in the study. Before being sent to the National Study Coordinator (AR) this data was de-identified (not traceable to the patient) by removing the patient's name, medical record number, etc., and giving the patient a unique study number. We implemented a double data entry model for potential errors in real-time. Data was entered twice by two different Data Entry personnel based on the same set of data collected in the paper CRFs. All data were reviewed, and values that appeared incongruent or out of range were manually validated by confirming the accuracy of the data with the Study Coordinator (AR). The database was validated and cleaned before the statistical analysis and the study database was locked to prevent any further changes, and to ensure data consistency and integrity for the statistical reporting and analysis.

Sample size calculation:

No statistical sample size calculation was performed a priori, and sample size was equal to the number of patients admitted to the participant's ICUs with confirmed COVID-19 during the study period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 31, 2023
• Est. primary completion date: April 17, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Severe community-acquired pneumonia due SARS CoV-2 infection and acute respiratory failure with microbiological confirmation (RT-PCR) according international guidelines

2. Age >= 16 years without upper limit

Exclusion Criteria:

1. Age < 16 years

2. Patients with SARS-CoV-2 infection without acute respiratory failure

Related Conditions & MeSH terms

• Communicable Diseases
• COVID-19
• Infections
• SARS-CoV2 Infection
• Severe Acute Respiratory Syndrome

Locations

Country	Name	City	State
Spain	Hospital Universitario de Tarragona Joan XXIII	Tarragona

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Universitari Joan XXIII de Tarragona.	Sociedad Española de Medicina Intensiva,critica y unidades coronarias

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Berenguer J, Borobia AM, Ryan P, Rodriguez-Bano J, Bellon JM, Jarrin I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR; COVID-19@Spain and COVID@HULP Study Groups. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021 Sep;76(9):920-929. doi: 10.1136/thoraxjnl-2020-216001. Epub 2021 Feb 25. — View Citation

Berenguer J, Ryan P, Rodriguez-Bano J, Jarrin I, Carratala J, Pachon J, Yllescas M, Arriba JR; COVID-19@Spain Study Group; Fundacion SEIMC-GESIDA; Hospital General Universitario Gregorio Maranon; Hospital Universitario La Paz; Hospital Infanta Leonor; Complejo Hospitalario Virgen de la Salud; Hospital Universitario Rafael Mendez; Hospital Universitario de Cruces; Hospital de Melilla; Hospital San Eloy de Barakaldo; Hospital Universitario Central de Asturias; Hospital General Universitario de Alicante; Hospital Virgen de la Victoria; Hospital Universitario Puerto Real; EOXI Pontevedra e Salnes; Hospital de Figueres; Hospital Sant Jaume de Calella; Hospital del Mar; Hospital Virgen de la Arrixaca; Hospital de Can Misses; Hospital de Sagunto; Hospital Clinico San Cecilio; Hospital Universitario Principe de Asturias; Parc Sanitari Sant Joan de Deu; Hospital Nuestra Senora de Gracia; HC Marbella Internacional Hospital; Hospital La Princesa; Hospital Josep Trueta; Hospital Dos de Maig; Hospital Arnau de Vilanova-Lliria; Hospital General Universitario de Elche; Hospital Clinico Universitario de Valencia; Complejo Asistencial de Avila; Hospital Comarcal de Alcaniz; Hospital Universitario Marques de Valdecilla; Hospital Quiron-Salud de Torrevieja; Hospital Universitario Miguel Servet; SCIAS, Hospital de Barcelona; Fundacion Hospital Universitario Alcorcon; Hospital Alvaro Cunqueiro; Complejo Asistencial Universitario de Salamanca; Hospital Universitario Severo Ochoa; Hospital CIMA-Sanitas; Hospital HLA Inmaculada; Hospital Universitario Rio Hortega; Hospital de Guadalajara; Hospital Universitario Infanta Sofia; Hospital Comarcal de Blanes; Hospital Universitari de Tarragona Joan XXIII; Hospital Universitario Basurto; Hospital Universitario de Canarias; Hospital Universitario de Gran Canaria Dr Negrin; Hospital Son Espases; Hospital Universitario de Mostoles; Complejo Hospitalario Universitario A Coruna; Hospital Costa del Sol; Hospital Clinico Universitario Lozano Blesa; Hospital Mutua de Terrassa; Hospital de la Plana; Hospital Virgen de la Concha-Complejo Asistencial de Zamora; Complejo Hospitalario Universitario Insular Materno-Infantil; Hospital de la Marina Baixa; Hospital Universitario Virgen Macarena; Hospital Universitari de Bellvitge; Hospital Universitario y Politecnico la Fe; Hospital Universitario del Vinalopo; Hospital de Sabadell (Parc Tauli); Hospital Clinic de Barcelona; Hospital Universitario de la Ribera; Fundacion Jimenez Diaz; Hospital Clinico Universitario de Valladolid; Hospital Clinico San Carlos; Hospital Santa Creu i Sant Pau; Clinica Universitaria de Navarra-Campus Madrid; Hospital Son Llatzer; Hospital General de la Defensa Gomez Ulla; Hospital Universitario de Alava; Hospital Santos Reyes; Hospital Dr Jose Molina Orosa; Hospital Vall d'Hebron; Hospital Universitario Rey Juan Carlos; Complejo Hospitalario Universitario Santa Lucia; Hospital Santa Barbara; Complejo Hospitalario Universitario de Ferrol; Hospital de l'Esperit Sant; Hospital Universitario los Arcos del Mar Menor; Hospital HLA Universitario Moncloa; Hospital Virgen del Puerto; Hospital Marina Salud de Denia; Hospital Universitario de Jerez; Hospital Reina Sofia de Tudela; Hospital Clinico Universitario de Santiago de Compostela; Hospital Universitario del Henares; Hospital Universitario Lucus Augusti; Hospital de Donostia; Hospital de Urduliz Alfredo Espinosa; Hospital de Mendaro; Hospital Juan Ramon Jimenez; Hospital de Tortosa Virgen de la Cinta; Hospital Riotinto; Hospital Vega Baja; Hospital Puerta de Hierro; Hospital Universitario de Getafe; Hospital General de la Palma; Hospital El Bierzo; Fundacion Hospital de Calahorra; Hospital Alto Deba; Hospital Universitario San Juan de Alicante; Hospital de Guadarrama; Hospital Universitario de Jaen; Hospital de Mataro; Hospital de Palamos; Hospital Universitario de Valme; Clinica Universitaria de Navarra-Campus Navarra; Hospital Clinica Benidorm; Hospital Doce de Octubre; Hospital Universitario Virgen del Rocio; Hospital Universitario Ramon y Cajal; Hospital Universitario San Pedro; Hospital Quiron A Coruna; HM Sanchinarro; Hospital Francesc de Borja; Complejo Hospitalario Universitario Nuestra Senora de La Candelaria; Hospital Universitario HM Monteprincipe; Hospital Universitario HM Puerta del Sur; Hospital Universitario HM Torrelodones; Hospital Universitario HM Madrid; Hospital Don Benito-Villanueva de la Serena; Hospital de Viladecans; Centro Nacional de Epidemiologia. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020 Nov;26(11):1525-1536. doi: 10.1016/j.cmi.2020.07.024. Epub 2020 Aug 4. — View Citation

Rodriguez A, Ruiz-Botella M, Martin-Loeches I, Jimenez Herrera M, Sole-Violan J, Gomez J, Bodi M, Trefler S, Papiol E, Diaz E, Suberviola B, Vallverdu M, Mayor-Vazquez E, Albaya Moreno A, Canabal Berlanga A, Sanchez M, Del Valle Ortiz M, Ballesteros JC, M — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epidemiologic and Clinical Characteristics and risk factors for ICU mortality in critically ill patients with COVID-19 in Spain	To determine demographics and clinical factors associated with ICU mortality at days-28 and ICU discharge	Observational period from ICU admission to data of discharge alive or date of death from any cause at days 28 of ICU length of stay and ICU discharge
Secondary	Support respiratory type and prognosis	Association between respiratory support used at ICU admission and ICU mortality	Observational period from ICU admission to data of discharge alive or date of death from any cause at days 28 of ICU length of stay and ICU discharge
Secondary	Comorbidities and prognosis	Association between different comorbidities (diabetes, obesity, hypertension, etc) and ICU mortality	Observational period from ICU admission to data of discharge alive or date of death from any cause at days 28 of ICU length of stay and ICU discharge

External Links

•   Spanisho Society of Critical Care web